Relmada Therapeutics News and Activities
Presence
Relmada Therapeutics develops biotechnology medicines for central nervous system and metabolic diseases. Its main services include drug research and clinical development for patients, healthcare providers, and research partners.
Relmada Therapeutics products and services overview:
- CNS therapies
- Depression treatments
- Metabolic disease drugs
- Drug discovery
- Clinical development
Revenue: ~$1 million
Employees: 30
Headquarters: Coral Gables, United States (USA)
Relmada Therapeutics is one of the...
Relmada Therapeutics is a company listed under the stock ticker RLMD (US).
Executives
View the org chart displaying its 17 main executives
Most searched biographies at Relmada Therapeutics
- Sergio Traversa, Chief Executive Officer and Director
- Charles Casamento, Chairman of the Board
- John Glasspool, Director
Popular executive movements at Relmada Therapeutics
- Michelle Noel has joined the company as Director of Data Management (posted on December 22 2025).
Create your alert
to follow the executive moves at Relmada Therapeutics.
Biotechnology
Relmada Therapeutics has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).
Popular M&A news in Biotechnology
- Clearside Biomedical has gone out of its bankruptcy protection (posted on July 15 2026).
- Attovia Therapeutics has filed its IPO. Its stock ticker will be ATTO. (posted on July 15 2026).
- The new name of ChemoTech is Neem’s Hill. (posted on July 15 2026).
Popular contacts in Biotechnology
News
Press releases by Relmada Therapeutics
- Relmada Therapeutics Announces Participation in the 2021 SVB Leerink Global Healthcare Conference :: Relmada Therapeutics, Inc. (RLMD)
- Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder :: Relmada Therapeutics, Inc. (RLMD)
- Relmada Therapeutics to Participate in Upcoming Investor Conferences :: Relmada Therapeutics, Inc. (RLMD)
- Press releases :: Relmada Therapeutics, Inc. (RLMD)
- Relmada Therapeutics Expands R&D Team, Appoints Paolo Manfredi, M.D., as Acting Chief Scientific Officer, Marco Pappagallo, M.D., as Acting Chief Medical Officer and Updates R&D Milestones :: Relmada Therapeutics, Inc. (RLMD)
- Press releases :: Relmada Therapeutics, Inc. (RLMD)
- Email alerts :: Relmada Therapeutics, Inc. (RLMD)
- IR calendar :: Relmada Therapeutics, Inc. (RLMD)
- Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market® :: Relmada Therapeutics, Inc. (RLMD)
- Relmada Therapeutics Announces Notice of Allowance for Patent in Canada Covering REL-1017 for Treatment of Psychiatric Symptoms :: Relmada Therapeutics, Inc. (RLMD)
- View more press releases Close
Social media about Relmada Therapeutics
- Relmada Therapeutics on Wikipedia, Google News & Yahoo Finance
- Relmada Therapeutics on LinkedIn, X (Twitter) & YouTube
